Puma Q4 net income $4.2M vs loss; FY loss narrows to $29.1M from $60.0M

PUMA BIOTECHNOLOGY, INC.

Q4 product revenue $51.0M (+2% YoY); total revenue $55.4M including $1.5M license and $2.9M royalty.
GAAP net income Q4 $4.2M ($0.10 EPS) vs loss of $15.0M ($0.38 loss) in Q4 2020.
FY 2021 net loss $29.1M ($0.72 loss) vs $60.0M loss ($1.52 loss); non-GAAP adjusted net income $3.5M.
Cash and securities $82.1M at Dec 31; operating cash flow $20.7M provided in FY 2021 vs $0.8M in FY 2020.
Key 2022 catalysts: pre-NDA meeting for neratinib HER2-mutant breast cancer, Phase II data in multiple indications.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.